Get an alert when QUBIS LIMITED files next

Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.

Free · confirmation link first · unsubscribe in one click

Cash

£17M

+16.9% vs 2024

Net assets

£116M

-29.9% vs 2024

Employees

0

Average over period

Profit before tax

-£39M

-81.5% vs 2024

Watchouts

Facts from the Companies House register and the latest accounts — not a rating

Accounts

2-year trend · Δ = latest vs prior filed period · latest reflected 2025-07-31

Metric Trend 2024-07-312025-07-31 Δ vs prior
Turnover £2,984,744£3,367,471 +12.8%
Operating profit £2,967,837£3,196,580 +7.7%
Profit before tax -£21,660,498-£39,307,993 -81.5%
Net profit -£21,660,498-£39,307,993 -81.5%
Cash £14,571,426£17,029,908 +16.9%
Total assets less current liabilities £165,100,179£115,745,833 -29.9%
Net assets £165,100,179£115,745,833 -29.9%
Equity £165,100,179£115,745,833 -29.9%
Average employees 00
Wages
Directors' remuneration

Values shown as filed in the company's annual accounts. indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show . About these numbers

Ratios

Computed from the line items above — sparklines read oldest → newest

Ratio Trend 2024-07-312025-07-31
Operating margin 99.4%94.9%
Return on capital employed 1.8%2.8%
Current ratio 22.54x13.26x
Interest cover 6.53x0.84x

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Margin ratios are hidden where reported turnover is too small relative to profit to yield a meaningful figure — typical of holding companies whose income is mostly subsidiary dividends rather than trading revenue. Sector-distribution context coming next.

Audit & accounting basis

Accounting basis
FRS 102
Reporting scope
Standalone (parent only)
Auditor
KPMG
Audit opinion
Unqualified (clean)
Going concern
Affirmed

“The directors have prepared the financial statements on the going concern basis as they do not intend to liquidate the Company or to cease its operations, and as they have concluded that the Company's financial position means that this is realistic. They have also concluded that there are no material uncertainties that could have cast significant doubt over its ability to continue as a going concern for at least a year from the date of approval of the financial statements ("the going concern period").”

Group structure

  1. QUBIS LIMITED · parent
    1. Acksen Limited 24.25% · United Kingdom · supply of instruments for monitoring electromagnetic radiation
    2. Biocolor Limited 20% · United Kingdom · development and supply of assay kits for tissue laboratories
    3. BXTA Nanotherapy Limited 28.68% · United Kingdom · commercialisation of nanotherapeutics to improve treatment outcomes for patients with cancer
    4. Green Lizard Technologies - Maymask 253 Limited 22.08% · United Kingdom · technological solutions
    5. Analytics Engines Limited 20.49% · United Kingdom · bespoke data analytics solutions
    6. Helix Research & Enterprise Limited 24.9% · United Kingdom · delivery of technology and research commercialisation programmes
    7. VascVersa Limited 22.3% · United Kingdom · human vascular stem cell generation
    8. Fjordstrong Limited 29.35% · United Kingdom · biodiversity survey solutions
    9. Phasora Limited 26.74% · United Kingdom · develop novel software to aid management of complex electricity distribution networks
    10. GenoMe Diagnostics Limited 25.18% · United Kingdom · development of molecular diagnostic tests
    11. Aramune Technologies Limited 33.59% · United Kingdom · development of natural immunomodulating agents
    12. AntennaWare Limited 21.06% · United Kingdom · high-performance wearable antenna technology
    13. Amply Discovery Limited 20.58% · United Kingdom · develop new biological molecules for anti-infective health and nutrition applications
    14. Rapid-Myco Technologies Limited 36.16% · United Kingdom · development of novel, rapid bacteria testing
    15. ReproGo Limited 37.44% · United Kingdom · vascular experts in stem cell therapy
    16. Medinect Bioservices Limited 27.66% · United Kingdom · research services in ophthalmic therapeutic development
    17. Ailse Vax Limited - Ailsebio Ltd 21.08% · United Kingdom · pioneering development of immune-oncology vaccines

Significant events

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

People

12 active · 45 resigned

Name Role Appointed Born Nationality
CHAUDHRY, Shehrezade Zafar Secretary 2024-10-01
BROUGHTON, Nicola Ann, Dr Director 2022-05-01 Sep 1971 British
CLARKE, Mary Siobhan Director 2025-11-01 Sep 1977 British
CLEMENTS, Archie Campbell Adair, Professor Director 2024-08-01 Jan 1974 Australian
CURRAN, Garrett Paul Director 2025-12-10 Dec 1971 British
DONOHOE, Marina Carmel Director 2026-02-02 Mar 1969 Irish
ELBORN, Joseph Stuart Director 2024-10-01 Oct 1958 Irish
KIRKPATRICK, Stephen Director 2025-11-01 Nov 1963 British
MCMULLAN, Eoin Director 2022-05-26 Dec 1991 Irish
O'HAGAN, Leonard Director 2024-10-01 May 1954 Irish
QUINN, David Director 2023-01-01 Apr 1968 British
TERRINGTON, Paul Alexander Director 2025-04-09 Jan 1964 British
Show 45 resigned officers
Name Role Appointed Resigned
BYERS, Helen Secretary 2016-01-01 2019-10-24
CONNOLLY, Margaret Secretary 2019-10-24 2024-10-01
HAMILTON, Heather Secretary 2014-11-25 2015-12-31
HAMILTON, Heather Secretary 2009-05-19 2009-12-01
MCCOMISKEY, Patrick, Dr Secretary 1984-10-11 2009-05-19
VAUGHAN, Loretta Maria Secretary 2009-12-02 2014-11-25
BAIN, George Sayers, Professor Sir Director 1984-10-11 2004-07-31
BAIRD, Brian Director 2015-09-01 2017-05-10
BELL, Robert Gordon Director 2008-01-29 2016-06-07
BRADY, Jayne Director 2020-05-19 2021-07-01
BRYAN, Frank Edward Director 2009-01-20 2017-01-31
CARTIN, Edward Director 1984-10-11 2004-05-11
CLAGUE, Joanne Director 2019-05-15 2022-07-31
CORMICAN, Hugh, Dr Director 2005-05-17 2012-02-14
CRAWFORD, R J, Prof Director 2001-01-31 2004-01-31
DOHERTY, J G, Dr Director 1984-10-11 2007-01-30
FLYNN, Emma, Professor Director 2019-05-15 2023-07-31
FULTON, John Francis, Professor Director 1984-10-11 2001-05-18
GALBRAITH, Wendy Margaret Director 2018-05-23 2019-05-15
GORMAN, Sean Patrick, Professor Director 2012-06-07 2016-03-14
GRAHAM, Francis Stuart Director 2001-10-24 2008-09-26
GREGSON, Peter John, Professor Director 2004-09-22 2013-07-31
HOGG, Brian W., Professor Director 1984-10-11 2004-07-01
HOPKINS, Anthony Strother Director 1984-10-11 2004-09-22
JOHNSTON, Rotha Geraldine Diane Director 2017-05-04 2025-12-10
KEATING, Bryan Stanley, Dr Director 2001-10-30 2009-01-20
KELLS, Ronald David Director 1984-10-11 2016-06-07
KELLY, Andrew Montgomery Director 1984-10-11 2001-05-18
KELLY, Maureen Director 2012-06-05 2013-12-03
KIRKPATRICK, Helen Director 2016-06-27 2025-12-10
LIOULIAS, Panos (Panayiotis Nicholaos) Director 2004-06-30 2011-10-30
MANN, John, Professor Director 2005-01-01 2006-01-31
MCCAUL, Brian Aidan Director 2014-03-20 2025-12-31
MCCORMAC, Gerry, Professor Director 2008-01-29 2010-04-30
MCELNAY, James Charles, Professor Director 2016-03-16 2019-01-22
MCKIE C B E, Peter, Dr Director 1984-10-11 2005-02-27
MERCER OBE, Henry B Director 1984-10-11 2001-05-18
MILLAR, Thomas Joseph, Professor Director 2012-06-07 2016-03-14
MURPHY, Denis Director 2005-05-17 2014-05-30
O'KANE, James Patrick Jude Director 1984-10-11 2022-05-01
REID, Gerard Colin Director 2011-11-03 2020-01-01
SLOAN, Aislinn, Dr Director 2012-06-05 2020-01-01
SPEED, Desmond Alfred Director 2017-05-04 2021-02-22
TEMPLETON, Brian O Director 1984-10-11 2004-06-30
WOOLFSON, Aaron David, Professor Director 2001-10-23 2012-05-29

Ownership

Persons with significant control

Name Kind Nature of control Notified Status
Queen's University Belfast Corporate entity Shares 75–100%, Appoints directors 2016-08-01 Active

Filing timeline

Last 20 of 238 total filings

Material constitutional events — rename, articles re-file, resolution

  • 2026-01-08 RESOLUTIONS Resolution
  • 2025-11-06 MA Memorandum articles
Date Type Category Description
2026-02-18 AP01 officers Appoint person director company with name date PDF
2026-02-18 TM01 officers Termination director company with name termination date PDF
2026-02-18 TM01 officers Termination director company with name termination date PDF
2026-02-18 TM01 officers Termination director company with name termination date PDF
2026-01-20 AP01 officers Appoint person director company with name date PDF
2026-01-08 RESOLUTIONS resolution Resolution
2025-11-28 AP01 officers Appoint person director company with name date PDF
2025-11-11 AP01 officers Appoint person director company with name date PDF
2025-11-10 AP01 officers Appoint person director company with name date PDF
2025-11-06 MA incorporation Memorandum articles
2025-10-30 AA accounts Accounts with accounts type full
2025-09-08 CS01 confirmation-statement Confirmation statement with no updates PDF
2025-06-19 AP01 officers Appoint person director company with name date PDF
2025-01-21 AP01 officers Appoint person director company with name date PDF
2024-11-15 AA accounts Accounts with accounts type full
2024-11-04 TM02 officers Termination secretary company with name termination date PDF
2024-11-04 CH03 officers Change person secretary company with change date PDF
2024-11-04 AP01 officers Appoint person director company with name date PDF
2024-11-04 AP03 officers Appoint person secretary company with name date PDF
2024-09-16 CS01 confirmation-statement Confirmation statement with no updates PDF

Public-record activity

Raw counts from Companies House — last 12–24 months

Filings
12

last 12 months

Capital events
0

last 24 months

Officers appointed
4

last 12 months

Officers resigned
3

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

Official Companies House page